Class summary at a glance.

Every drug in the Macrolide Antibacterial class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 1tracked in Part D
CY24 Part D spend: $241.3Mcombined across class
Total Rx claims: 53K41K unique beneficiaries
Generic mfrs (active): 3across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Fidaxomicin

Brand: DIFICID · 53K Part D claims (CY24) · 41K beneficiaries · First FDA approval: 2011-05-27

3 generic mfrs 128 plans require PA

Low NADAC$193.67

→

Avg plan cost$207.42

Part D spend $241.3M 1× spread, current vs floor

Class share

100%

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.